Medidata Secures Highest Leadership Position in Everest Group’s First Life Sciences Clinical Trial Management System Products PEAK Matrix® Assessment
Reading Time: 3 minutes New York, United States: Medidata, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, has been recognized as a leader in Everest Group’s first-ever Life Sciences Clinical Trial Management System Products PEAK Matrix®
Form 8.3 – Anglogold Ashanti plc
Reading Time: 4 minutes FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Ninety One UK Ltd (b) Owner
CyberArk and Wiz Team Up To Provide Complete Visibility and Control for Cloud-Created Identities
Reading Time: 4 minutes Petach Tikva, Israel & Newton, Mass., United States: CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced a high-impact partnership with leading cloud security provider Wiz. The two companies are joining forces to enable customers to strengthen their multi-cloud
Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings
Reading Time: 2 minutes Optomed Plc Stock Exchange Release 14 November 2024 at 11.00, Helsinki Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings Optomed Plc (“Optomed” or the “Company”) has received a notification in accordance with the Chapter 9, Section
Pihlajalinna Plc: Managers’ transactions – Pihlajalinna Oyj
Reading Time: < 1 minute Pihlajalinna Plc Managers’ transactions 14 November 2024 at 10:30 a.m. Pihlajalinna Plc: Managers’ transactions Pihlajalinna Plc has received the following notification on 13 November 2024: Person subject to the notification requirementName: Seppo KariniemiPosition: Other senior manager lssuer: Pihlajalinna OyjLEI: 74370058MTRLEDOCHV67
Aonic AB (publ) publishes interim report for Q3 2024
Reading Time: < 1 minute Press releaseTHU, November 14, 2024, 09.00 CEST Aonic AB (publ) has today published its Q3 2024 report on the company’s website https://aonic.co/. The report is available on the company’s website as a PDF. For more information:Paul Schempp, CEO +46 76 344
Merck Foundation Marking “World Diabetes Day” by Providing out of 2080 Scholarships, 830 Scholarships for Diabetes and Hypertension in 52 Countries
Reading Time: 4 minutes Merck Foundation, the philanthropic arm of Merck KGaA Germany, marks ‘World Diabetes Day 2024’ together with Africa’s First Ladies, Ministries of Health, Medical Societies and Academia, through their “Nationwide Diabetes & Hypertension Blue Points Program”. Senator, Dr. Rasha Kelej, CEO of Merck Foundation emphasized, “At Merck Foundation, we
Information about the Annual Report 2023/2024
Reading Time: 2 minutes Diamyd Medical today publishes its Annual Report for 2023/24. The Company is in an expansive phase where positive feedback has been received from the US Food and Drug Administration (FDA) regarding the possibility of earlier market approval. The Annual Report is published
Ram Film Factory’s ‘Trending’ Tamil Movie to Hit Theatres This Month
Reading Time: 3 minutes Three more films are in the pipeline-the pre-production of one of them is completed, and script for another is finalised Ram Film Factory is launched by Ms. Meenakshi Anand, daughter-in-law of late Mr. K. Govindan, a celebrated costume designer
Bioretec Ltd’s business review January–September 2024: Launch of the RemeOs™ Trauma Screw in the U.S. is proceeding to the next phase, EU authorization in the final stage
Reading Time: 7 minutes Bioretec Ltd Company announcement 14 November 2024 at 8:45 a.m. This announcement summarizes Bioretec Ltd’s business review for January–September 2024. The complete business review is attached to this release as a PDF file and available on the company’s website at https://bioretec.com/investors/investors-in-english/releases. July